Thelansis

Buerger’s Disease (BD) Market Outlook Thelansis’s “Buerger’s Disease (BD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Buerger’s Disease (BD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajector...

Buerger’s Disease (BD) Market Outlook Thelansis’s “Buerger’s Disease (BD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Buerger’s Disease (BD)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Buerger’s Disease (BD) Overview Buerger’s Disease, or Thromboangiitis obliterans (TAO), is a distinctive nonatherosclerotic and segmental inflammatory condition primarily affecting the small and medium-sized arteries and veins in the extremities. This vascular disorder is characterized by acute-phase lesions, marked by occlusive cellular thrombosis and inflammation spanning all vessel wall layers, earning it the classification of...

 Buerger's Disease, or Thromboangiitis obliterans (TAO), is a distinctive nonatherosclerotic and segmental inflammatory condition primarily affecting the small and medium-sized arteries and veins in the extremities. This vascular disorder is characterized by acute-phase lesions, marked by occlusive cellular thrombosis and inflammation spanning all vessel wall layers, earning it the classification of vasculitis. Despite extensive research, there is no consistent pattern in HLA haplotypes among individuals with Buerger's disease. However, in European nations, there appears to be a higher prevalence of HLA-A9 and HLA-B5 antigens, suggesting a possible genetic component in certain populations. The primary demographic at heightened risk for Buerger's disease consists of heavy smokers. Particularly susceptible are men of Eastern European descent under the age range of 20 to 40. This specific demographic subgroup demonstrates an increased vulnerability to the disease. Additionally...

 Buerger’s Disease (BD) or Thromboangiitis obliterans (TAO) is a nonatherosclerotic, segmental inflammatory disease that most commonly affects the small and medium-sized arteries and veins in the upper and lower extremities. In the characteristic acute-phase lesion, in association with occlusive cellular thrombosis, the acute inflammation involving all layers of the vessel wall led TAO to be classified as vasculitis. There is no consistent pattern in HLA haplotypes among patients with Buerger’s disease. However, in the European nations, there was a preponderance of HLA-A9 and HLA-B5 antigens. ·        In 2019, the overall incidence of cases of Buerger’s disease (BD) was reported to be 12.5 to 28 cases per 100,000 population in the USA. However, the numbers are high in European and APAC populations. Thelansis’s “Buerger’s Disease (BD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease over...